Last updated: February 2, 2026
Summary
Albiglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed primarily for type 2 diabetes mellitus (T2DM) management, has experienced a shifting clinical and market landscape. Once considered a promising injectable therapy, its development was discontinued by GlaxoSmithKline (GSK) in 2018. This comprehensive review covers recent clinical trial updates, market dynamics, competitive positioning, and future projections for albiglutide within the broader GLP-1 receptor agonist class.
What is the Clinical Trials Status of Albiglutide?
Current Clinical Trial Landscape
Albiglutide’s development trajectory was notably impacted by GSK's decision to cease its commercialization. However, ongoing or recently completed trials have provided insights into its therapeutic profile.
| Trial Status |
Details |
Status Date |
Purpose |
| Completed |
Evaluation of cardiovascular outcomes in T2DM (Harmony Outcomes) |
March 2018 |
Assess CV safety and efficacy |
| Not recruiting / Terminated |
Further efficacy and dosing studies |
N/A |
Evaluate if additional indications or formulations are viable |
| Pending / Unlisted |
Biometric registries or retrospective analyses |
N/A |
Understand long-term safety in real-world data |
Key Clinical Highlights
-
Harmony Outcomes Trial (NCT01869562): Published in 2018, enrolled over 9,000 patients, assessing CV safety of albiglutide. Results confirmed non-inferiority to placebo, aligning with expectations for GLP-1 receptor agonists.
-
Additional Trials: Limited updates on ongoing efficacy trials after 2018, with no new pivotal studies announced post-discontinuation.
Implications
Despite promising clinical data, especially regarding cardiovascular benefits (a key attribute for GLP-1 agents), the discontinuation highlighted safety, market adoption challenges, and strategic reprioritization by GSK.
Market Analysis of Albiglutide
Market Position Before Discontinuation
| Parameter |
Details |
| Initial Approval & Launch |
2014 in the U.S. and Europe as a once-weekly GLP-1 receptor agonist |
| Indications |
T2DM, with some cardiovascular outcome trial data |
| Pricing (Approximate) |
~$9-$12 per dose (weekly injection), positioning it as a premium therapy |
| Market Share (Pre-2018) |
Estimated at 1-2% within GLP-1 class; behind rivals like dulaglutide and semaglutide |
| Sales Revenue (2018) |
~$135 million globally before discontinuation |
Competitive Landscape
| Product |
Developer |
Market Share (2018) |
Unique Selling Point |
Status |
| Liraglutide |
Novo Nordisk |
~70% |
Established, flexible dosing, weight loss |
Market leader, continuous sales |
| Dulaglutide |
Eli Lilly |
~20% |
Once-weekly, favorable safety profile |
Continues to grow in market |
| Semaglutide |
Novo Nordisk |
~10% |
Potent efficacy, weight loss (Wegovy) |
Rapidly expanding, high adoption |
| Albiglutide |
GSK |
~1-2% |
Cardiovascular trial data |
Discontinued in 2018, no longer marketed |
Market Dynamics Post-Discontinuation
- Shift in Focus: Many pharmaceutical companies pivoted toward oral GLP-1 formulations (e.g., Oral Semaglutide by Novo Nordisk) due to patient preference.
- Partnerships & Biosimilars: No biosimilar activity for albiglutide yet, and no major partnerships post-2018.
- Therapeutic Preference: The market favors drugs with proven cardiovascular benefits, weight loss properties, and increased convenience.
Regulatory & Policy Factors
- Diabetes and Cardiovascular Disease (CVD) guidelines (ADA 2022) increasingly recommend GLP-1 receptor agonists with proven CV benefits (e.g., semaglutide, dulaglutide).
- FDA & EMA continued safety monitoring for existing GLP-1 agents but did not find enough compelling reasons to revive albiglutide's approval.
Future Market Projections for Albiglutide
Market Re-entry Probability
| Scenario |
Likelihood |
Rationale |
Potential Impact |
| Revival via New Indication |
Low |
GSK has no ongoing clinical trials; thus, reintroduction would require restarting development efforts |
Limited unless new data emerge |
| Development of Biosimilars |
Very Low |
No biosimilar development announced; high barriers for a discontinued molecule |
Unlikely |
| Strategic Partnership or Acquisition |
Low |
Industry interest in late-stage GLP-1 compounds could aid revival, but unlikely without compelling data |
Highly speculative |
Forecasted Market Share (2025-2030)
- Undisrupted GLP-1 Class: Dominated by semaglutide and dulaglutide, with combined market share >80%.
- Albiglutide (Hypothetical Revival): Potential small niche (<1%) driven by CV benefits, if reintroduced with new data.
- Revenue Projection: Likely negligible unless significant new development occurs; ongoing sales expected to decline to <$10 million/year due to market displacement.
Barriers to Re-Entry
| Barrier |
Impact |
| Market Entrenchment of Competitors |
Well-established, superior profiles; high switching barriers |
| Lack of New Clinical Data |
No ongoing trials; risk of regulatory hurdles if re-entered |
| Manufacturing & Supply Chain |
GSK’s manufacturing capabilities probably unused post-discontinuation |
Opportunities in the Ecosystem
- Combination Therapies: Potential if combined with oral agents or other biologics.
- New Formulations: Long-acting, auto-injectors, or oral formulations could boost applicability.
- Personalized Medicine: Identifying subpopulations who benefit most from the CV data.
Comparison Table: Albiglutide vs. Major GLP-1 Agents
| Feature |
Albiglutide |
Dulaglutide |
Semaglutide |
Liraglutide |
| Approval Year |
2014 |
2014 |
2019 (marketed as weekly) |
2010 |
| Dosing Frequency |
Weekly |
Weekly |
Weekly |
Daily |
| Mechanism |
GLP-1 receptor agonist |
GLP-1 receptor agonist |
GLP-1 receptor agonist |
GLP-1 receptor agonist |
| Cardiovascular Data |
Yes (Harmony Outcomes) |
Yes (REWIND, others) |
Yes (SUSTAIN 6, PIONEER 6) |
Yes (LEADER, others) |
| Market Status |
Discontinued |
Active |
Active |
Active |
| Market Share (2018) |
1-2% |
~20% |
~10% |
~70% |
Key Takeaways
- Albiglutide's clinical development concluded with notable cardiovascular safety data but failed to demonstrate competitive advantages or market adoption.
- Market dynamics favor agents with proven efficacy, CV benefits, weight loss effects, and flexible dosing; albiglutide lags behind in all areas.
- Future prospects for albiglutide remain minimal unless new clinical data or strategic collaborations emerge.
- The competitive landscape has intensified with oral formulations and high-efficacy agents, decreasing the likelihood of market re-entry.
- Pharmaceutical investment in similar biologics should prioritize agents with established CV benefits, versatile dosing, and patient-centric features.
FAQs
Q1: Why was albiglutide discontinued by GSK?
Albiglutide was discontinued in 2018 due to strategic portfolio realignment and its relatively modest market share compared to competitor GLP-1 agents with superior efficacy and convenience profiles.
Q2: Are there any ongoing clinical trials for albiglutide?
No significant active trials are known post-2018; most studies have been completed, and the drug has been withdrawn from the market.
Q3: Can albiglutide be considered for reintroduction?
Reintroduction is unlikely without new clinical trial data demonstrating distinct advantages, especially CV benefits, or an unmet market need.
Q4: What are the main competitors of albiglutide?
Dulaglutide, semaglutide, and liraglutide are the main active competitors, with established efficacy and market share.
Q5: Is there any ongoing biosimilar development for albiglutide?
No biosimilar development has been announced or is in progress for albiglutide to date.
References
- Vilsbøll T, et al. "Albiglutide: a GLP-1 receptor agonist for T2DM." Current Diabetes Reports, 2020.
- GSK. "Albiglutide (Tanzeum): clinical trial data and discontinuation statement," 2018.
- American Diabetes Association. "Standards of Medical Care in Diabetes—2022."
- ClinicalTrials.gov. Search for albiglutide related studies.
- Market Research Reports. "GLP-1 Receptor Agonists Global Market," 2022.
Note: As of the current date, albiglutide remains withdrawn from the market with no active development projects. Future market re-entry remains highly speculative.
